Products dimethyl fumarate
dimethyl fumarate Approved UNKNOWN 🔥 Hot Feb 1, 2015 → Dec 1, 2018
About dimethyl fumarate dimethyl fumarate is a approved stage product being developed by Biogen for Multiple Sclerosis. The current trial status is unknown. This product is registered under clinical trial identifier NCT03092544. Target conditions include Multiple Sclerosis.
Clinical Trials (20) NCT ID Phase Status Start Completion Indication NCT05658484 Approved Completed Jun 9, 2023 Apr 12, 2025 Multiple Sclerosis NCT04756687 Pre-clinical Completed Mar 10, 2021 Jun 15, 2021 Multiple Sclerosis NCT04221191 Pre-clinical Completed Aug 19, 2019 Sep 14, 2022 Multiple Sclerosis, Relapsing-Remitting NCT02969304 Pre-clinical Completed Dec 30, 2016 Mar 2, 2017 Multiple Sclerosis NCT02675413 Approved Withdrawn Apr 1, 2016 Apr 1, 2016 Multiple Sclerosis NCT02555215 Phase 3 Completed Feb 22, 2016 Sep 24, 2018 Multiple Sclerosis, Relapsing-Remitting NCT02644083 Pre-clinical Terminated Feb 1, 2016 Jul 1, 2018 Multiple Sclerosis NCT02410200 Phase 2 Completed Sep 30, 2015 Sep 23, 2016 Multiple Sclerosis, Relapsing-Remitting NCT02525874 Phase 3 Completed Aug 11, 2015 Apr 23, 2018 Multiple Sclerosis, Relapsing-Remitting NCT02472938 Approved Withdrawn Jul 1, 2015 Jul 1, 2020 Relapsing Remitting Multiple Sclerosis NCT02519413 Pre-clinical Completed Jul 1, 2015 Feb 1, 2016 Multiple Sclerosis NCT02090348 Approved Withdrawn Jun 1, 2015 Oct 1, 2017 Relapsing-Remitting Multiple Sclerosis NCT02461069 Approved Completed May 6, 2015 May 7, 2018 Multiple Sclerosis, Relapsing-Remitting NCT02323269 Pre-clinical Terminated May 1, 2015 Mar 1, 2016 Multiple Sclerosis, Relapsing-Remitting NCT02430532 Phase 3 Terminated May 1, 2015 Jan 1, 2016 Multiple Sclerosis, Secondary Progressive NCT02736279 Pre-clinical UNKNOWN May 1, 2015 Dec 1, 2020 Multiple Sclerosis NCT02428231 Phase 3 Terminated Apr 1, 2015 Jan 1, 2016 Multiple Sclerosis NCT02343159 Approved Terminated Feb 28, 2015 Apr 15, 2016 Multiple Sclerosis NCT03092544 Approved UNKNOWN Feb 1, 2015 Dec 1, 2018 Multiple Sclerosis NCT02125604 Approved Completed Jun 1, 2014 Mar 1, 2016 Relapsing-Remitting Multiple Sclerosis
Product Company Stage Hype Score Placebo + Pirtobrutinib Eli Lilly Phase 2 Abemaciclib, dexamethasone, ixazomib, pomalidomide + Enasidenib, dexamethasone, ixazomib, pomalidomide + Cobimetinib, dexamethasone, ixazomib, pomalidomide + Erdafitinib, dexamethasone, ixazomib, pomalidomide + Venetoclax, dexamethasone, ixazomib, pomalidomide + Daratumumab, dexamethasone, ixazomib, pomalidomide + Belantamab mafodotin, dexamethasone, ixazomib, pomalidomide + Selinexor, dexamethasone, ixazomib, pomalidomide Eli Lilly Phase 1/2 NEX-20A Nanexa AB Phase 1 agenT-797 MiNK Therapeutics Phase 1 Duloxetine Hydrochloride (HCI) + Placebo Eli Lilly Phase 3 Temferon Genenta Science Phase 1/2 CT-P44(Daratumumab) + Darzalex Faspro(Daratumumab) Celltrion Phase 3 CT-P53 + US-Ocrevus + EU-Ocrevus Celltrion Phase 3 CS-0777 tablets + CS-0777 tablets + CS-0777 tablets Daiichi Sankyo Phase 1 ASP7487, Velcade, Dexamethasone Astellas Pharma Phase 1/2 PHE885 Novartis Phase 2 Mirabegron + Placebo Astellas Pharma Approved Solifenacin Succinate + Solifenacin Succinate + Oxybutynin Hydrochloride + Placebo Astellas Pharma Approved Denileukin Diftitox (Ontak) Eisai Phase 1 Palonosetron Eisai Phase 2 BIW-8962 Kyowa Kirin Phase 1 KRN125(pegfilgrastim), PLR001(plerixafor) + KRN8601(filgrastim), PLR001(plerixafor) Kyowa Kirin Phase 2 KW-2478 + Bortezomib Kyowa Kirin Phase 1/2 ONO-2808 + Placebo Ono Pharmaceutical Phase 2 KW-2478 Kyowa Kirin Phase 1
Other Products from Biogen